How Fitzgerald was paid
$956,966 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Total |
|---|---|---|---|
| Robert Michael DudleyFormer Chief Executive Officer | $85,432 | — | $85,432 |
| Thomas A. FitzgeraldInterim Chief Executive Officer, Vice President and Chief Financial Officer | $255,076 | $701,890 | $956,966 |
What changed and why
- $957K$956,966 was Mr. Fitzgerald’s 2024 total compensation, including $701,890 in option awards and $255,076 in salary.
- 35%35% was Mr. Fitzgerald’s 2024 target bonus; no bonuses were awarded for 2023.
- $34,607.70$34,607.70 was Mr. Dudley’s severance under a transition agreement after his January 13, 2024 resignation.
- 2024 options granted to the named executive officer used time-based vesting.
- Mr. Fitzgerald’s 2024 salary reflected voluntary reductions during various payroll periods.
- Pay Governance continued as the compensation committee’s independent compensation consultant.
Other Transcode Therapeutics proxy statements
- 2026 proxy statement
Philippe P. Calais paid $373,808.
Filed Jun 02, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.